Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
86 hedge funds and large institutions have $128M invested in Anthera Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 21 reducing their positions, and 7 closing their positions.
186% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
86% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 21
45% more call options, than puts
Call options by funds: $3.29M | Put options by funds: $2.27M
18% more funds holding
Funds holding: 73 → 86 (+13)
10% less capital invested
Capital invested by funds: $142M → $128M (-$13.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.1M |
| 2 |
SCM
Sio Capital Management
New York
|
+$5.4M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.68M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$3.11M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$3.23M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.07M |
| 3 |
BC
Broadfin Capital
New York
|
-$1.88M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.83M |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$1.53M |
ANTH Hedge Fund Activity: Q3 2015 in Review
86 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q3 2015, worth a combined $128M — down 9.5% from $142M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ANTH positions and 7 closed out — a net gain of 13 holders — while 39 added to existing stakes and 21 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $18.1M. The largest seller was Rhenman & Partners Asset Management, cutting an estimated $3.23M.
- 86 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q3 2015, up from 73 in Q2 2015.
- Funds reported $128M of Anthera Pharmaceuticals, Inc. stock for Q3 2015, down 9.5% quarter-over-quarter.
- 20 funds opened new Anthera Pharmaceuticals, Inc. positions in Q3 2015 and 7 closed out, a net change of +13 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q3 2015 was Fidelity Investments, an estimated $18.1M added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q3 2015 was Rhenman & Partners Asset Management, an estimated $3.23M sold.
Based on aggregated 13F filings for Q3 2015.